or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    ITCI B 1.66 4.49
    MRK A 0.35 4.01
    CTLT C 0.09 3.91
    LLY D 1.21 3.89
    PRGO C 1.85 3.86
    OGN B -0.05 3.82
    AXSM D -0.03 3.72
    PFE F 0.67 3.69
    JAZZ F 1.33 3.60
    RPRX D 0.21 3.59
    JNJ F -0.13 3.58
    VTRS C 0.97 3.57
    BMY F 1.24 3.51
    ZTS D 2.65 3.29
    ELAN F 1.69 3.22
    CORT F 3.11 2.78
    ARVN D 1.58 2.10
    EYPT D -0.37 1.97
    AMPH D 1.03 1.69
    SAVA B 1.52 1.65
    TARS D -1.99 1.46
    PBH C 0.11 1.14
    PCRX F 2.43 1.02
    HRMY F 1.94 0.94
    LQDA D 0.73 0.89
    COLL C 1.28 0.89
    LBPH C 0.57 0.84
    INVA C 0.73 0.82
    LGND D 1.73 0.73
    SUPN D 1.09 0.70
    AMRX B 0.59 0.64
    ANIP B 0.34 0.52
    RVNC F 5.93 0.51
    PLRX F 0.67 0.50
    OCUL F 0.00 0.46
    EOLS D -0.52 0.38
    TBPH B 0.33 0.32
    XERS F 0.59 0.29
    FULC D -0.42 0.22
    MRNS F -1.76 0.05

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Pain Pharmaceutical Medicine Pharmaceutical Products S&P 500 Alzheimer's Disease Animal Health Drugs Neuroscience Biotechnology Depression Diabetes Disease Hypertension Life Sciences Medication Pharmacology Suspension Antibiotics
    Industries: Biotechnology Drug Manufacturers - Specialty & Generic Drug Manufacturers - Major Drug Manufacturers - General Medical Distribution

    Recent News for Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF & its Holdings

    Date Stock Title
    Apr 26 PFE Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
    Apr 26 PFE Dividend Roundup: MetLife, General Motors, Pfizer, Citigroup, and more
    Apr 26 PFE Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
    Apr 26 PFE UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
    Apr 26 PFE U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
    Apr 26 PFE Should You Buy Moderna Before May 12?
    Apr 26 MRK Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
    Apr 26 BMY Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
    Apr 26 BMY Q1 2024 Bristol-Myers Squibb Co Earnings Call
    Apr 26 PFE Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
    Apr 26 BMY Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
    Apr 26 ANIP Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
    Apr 25 BMY Bristol Myers Squibb stock tumbles on cost-cutting initiative
    Apr 25 BMY Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off
    Apr 25 MRK Merck (MRK) Q1 2024 Earnings Call Transcript
    Apr 25 MRK Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
    Apr 25 BMY Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
    Apr 25 BMY Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
    Apr 25 MRK Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript
    Apr 25 BMY Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
    Exchange Traded Funds
    Back to the Main PILL Page...